Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.73 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.67 |
| ▸ | BCL2 | P10415 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 3/20 | 0.65 |
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | PPARA | Q07869 | 2/20 | 0.63 |
| ▸ | YAP1 | P46937 | 1/20 | 0.62 |
| ▸ | MME | P08473 | 1/20 | 0.61 |
| ▸ | CPA1 | P15085 | 1/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.61 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193473 | 1.00 | PTPN1 (0.73) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL2891538 | 1.00 | PTPN1 (0.73) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL28267499 | 0.95 | PTPN1 (0.77) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL28267496 | 0.95 | PTPN1 (0.77) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL464744 | 0.93 | PTPN1 (0.65) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| Phenylalanine Methyl Ester SCHEMBL28119144 | 0.91 | PTPN1 (0.63) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL3350988 | 0.91 | BCL2 (0.64) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL9752771 | 0.91 | BCL2 (0.64) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL9752770 | 0.91 | BCL2 (0.64) | PTPN1ITGB3ITGA2BBCL2PPARG | |
| SCHEMBL3500186 | 0.91 | BCL2 (0.64) | PTPN1ITGB3ITGA2BBCL2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188231-B | Synthesis and application of pasireotide pentapeptide intermediate | 中国医学科学院药物研究所 | 2021-10-22 | — | — | CN | claimed |
| CN-106188231-A | The synthesis of pasireotide pentapeptide intermediate and application | 中国医学科学院药物研究所 | 2016-12-07 | — | — | CN | claimed |
| US-12625431-B2 | EUV resist underlayer film-forming composition | NISSAN CHEMICAL CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2024-04-18 | — | — | US | disclosed |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110099682-B | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-0195667-A2 | Cardiotonic quinazoline derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1986-09-24 | — | — | EP | disclosed |
| EP-0190588-A1 | Quinazolino-1,4-benzodiazepin-6,9-diones, processes for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-08-13 | — | — | EP | disclosed |
| US-4554272-A | CHOLECYSTOKININ INHIBITORS | MERCK & CO., INC. (US) | 1985-11-19 | — | — | US | disclosed |
| US-4535169-A | 5H-6-oxo-2,3,4,4a,7,7a-hexahydropyrano[2,3-b]pyrrole and the preparation thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1985-08-13 | — | — | US | disclosed |
| US-4407746-A | Cyclohexyl and phenyl substituted enkephalins | G. D. SEARLE & CO. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4301045-A | RESIN PEPTIDES | ARMOUR PHARMACEUTICAL COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4146614-A | TREATMENT OF SCHIZOPHRENIA | STATE OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
| US-3974135-A | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for producing the same | FOLKERS KARL | 1976-08-10 | — | — | US | disclosed |
| US-3953416-A | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same | FOLKERS KARL | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | PTPN1 827/4885ITGB3 2864/4885ITGA2B 3805/4885 |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | PTPN1 1021/4885ITGB3 314/4885ITGA2B 442/4885 |
| US-12625431-B2 | EUV resist underlayer film-forming composition | EEF1A1, ARF1, EMG1 | PTPN1 912/4885ITGB3 358/4885ITGA2B 496/4885 |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | PTPN1 779/4885ITGB3 3292/4885ITGA2B 3936/4885 |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | PTPN1 786/4885ITGB3 3310/4885ITGA2B 3985/4885 |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | PTPN1 1161/4885ITGB3 269/4885ITGA2B 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.